Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,608.40GBp
9:00pm IST
Change (% chg)

18.00 (+1.13%)
Prev Close
1,590.40
Open
1,593.00
Day's High
1,610.00
Day's Low
1,589.40
Volume
5,868,163
Avg. Vol
8,526,807
52-wk High
1,612.80
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

GSK sees positive headline results from VIIV HC Atlas study
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - GlaxoSmithKline PLC ::POSITIVE HEADLINE RESULTS FOR VIIV HC ATLAS STUDY.POSITIVE HEADLINE RESULTS FOR VIIV HC ATLAS STUDY.REPORTS POSITIVE 48-WEEK RESULTS FOR FIRST PIVOTAL, PHASE III STUDY FOR NOVEL, LONG-ACTING, INJECTABLE HIV-TREATMENT REGIMEN.FULL RESULTS FROM STUDY WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.  Full Article

GSK Names Ex-HSBC Finance Director Iain Mackay As CFO
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - GlaxoSmithKline PLC ::IAIN MACKAY APPOINTED GSK CHIEF FINANCIAL OFFICER.IAIN MACKAY HAS ALSO BEEN APPOINTED AS AN EXECUTIVE DIRECTOR TO GSK BOARD.MACKAY WILL JOIN COMPANY ON 14 JANUARY 2019.SIMON DINGEMANS WILL CONTINUE TO BE ACCOUNTABLE AS CFO FOR GSK'S FINANCIAL GOVERNANCE THROUGH MARCH 2019.MACKAY JOINS GSK FROM HSBC.THERE WILL BE TRANSITION PERIOD FROM 14 JANUARY WHEN MACKAY IS CFO DESIGNATE, WITH HIM TAKING FORMAL ACCOUNTABILITY FROM 1 APRIL.  Full Article

EU Medicines Agency Recommends Approval Of GSK's Paediatric Asthma Drug Nucala
Friday, 27 Jul 2018 

July 27 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - CHMP RECOMMEND NUCALA (MEPOLIZUMAB) FOR TREATMENT OF SEVERE EOSINOPHILIC ASTHMA PAEDIATRIC PATIENTS IN EUROPE.  Full Article

GSK CEO: Board's Position on Group Structure Unchanged
Wednesday, 25 Jul 2018 

July 25 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE CEO SAYS BOARD'S POSITION ON GROUP STRUCTURE REMAINS UNCHANGED.GLAXOSMITHKLINE CEO SAYS BOARD LIKES CURRENT DIVERSIFIED STRUCTURE.GLAXOSMITHKLINE CEO SAYS ALL THREE BUSINESSES MUST CONTINUE TO PERFORM IN THEIR OWN RIGHT.GLAXOSMITHKLINE CEO SAYS NOT SURE WHAT DROVE RECENT COMMENTARY ON STRUCTURE OF GROUP.GLAXOSMITHKLINE CEO SAYS U.S. NET PRICES HAVE DOWN IN RECENT YEARS.GLAXOSMITHKLINE CEO SAYS HAVEN'T PUT A U.S. PRICE UP SINCE GOVERNMENT BLUEPRINT ANNOUNCED.GLAXOSMITHKLINE CEO SAYS WE EXPECT PHARMA RESEARCH AND DEVELOPMENT INVESTMENTS WILL INCREASE.GLAXOSMITHKLINE CFO SAYS RESTRUCTURING EFFORTS WILL FOCUS ON OPTIMISING SUPPLY CHAIN.GLAXOSMITHKLINE CFO SAYS RESTRUCTURING PLAN MAKES US COMFORTABLE WE CAN SUPPORT DIVIDEND WHILE INVESTING IN PHARMA.GLAXOSMITHKLINE CFO SAYS WE EXPECT TO DO MORE BUSINESS DEVELOPMENT.GLAXOSMITHKLINE CFO SAYS DEALS WILL INCLUDE BOTH IN-LICENSING AND OUT-LICENSING OF NON-CORE ASSETS.GLAXOSMITHKLINE CFO SAYS CONSUMER BUSINESS GIVES US CASH FLOW TO HELP FUND BUSINESS DEVELOPMENT.GLAXOSMITHKLINE CEO SAYS BIGGEST ISSUE AROUND BREXIT IS SECURING SUPPLY OF DRUGS AND VACCINES.  Full Article

Glaxosmithkline Says U.S. FDA Approves Krintafel For Radical Cure Of P. Vivax Malaria
Saturday, 21 Jul 2018 

July 20 (Reuters) - GlaxoSmithKline PLC ::US FDA APPROVES KRINTAFEL (TAFENOQUINE) FOR RADICAL CURE OF P. VIVAX MALARIA.  Full Article

GSK Board Considers Break-Up Of Group - FT
Saturday, 21 Jul 2018 

July 20 (Reuters) - :GSK BOARD CONSIDERS BREAK-UP OF GROUP, CHAIRMAN WEIGHS SPINNING OFF CONSUMER DIVISION AFTER PRESSURE FROM INVESTORS - FT, CITING SOURCES.  Full Article

GlaxoSmithKline Says James Ford Appointed General Counsel
Thursday, 12 Jul 2018 

July 12 (Reuters) - GlaxoSmithKline PLC ::JAMES FORD APPOINTED GSK GENERAL COUNSEL.JAMES FORD APPOINTED GSK GENERAL COUNSEL.JAMES REPLACES DAN TROY WHO WILL LEAVE GSK AFTER 10 YEARS AS GENERAL COUNSEL.  Full Article

GlaxoSmithKline Says Signs Deal With Roivant Unit To Purchase Rights To Tapinarof
Thursday, 12 Jul 2018 

July 12 (Reuters) - GlaxoSmithKline PLC ::ROIVANT SUBSIDIARY DERMAVANT SCIENCES SIGNS AGREEMENT WITH GSK TO PURCHASE RIGHTS TO TAPINAROF.TOTAL CONSIDERATION OF £250 MILLION, INCLUDING AN INITIAL PAYMENT OF £150 MILLION AND A POTENTIAL FUTURE MILESTONE PAYMENT OF £100 MILLION.  Full Article

Glaxosmithkline Reports 8.3 Pct Stake In Translate Bio As Of June 27 - Sec FILING
Friday, 6 Jul 2018 

July 5 (Reuters) - Glaxosmithkline Reports 8.3 Pct Stake In Translate Bio Inc ::GLAXOSMITHKLINE SAYS THROUGH UNIT, ACQUIRED FROM TRANSLATE BIO 269,230 SHARES OF STOCK ON JULY 2 IN TRANSLATE'S IPO AT PUBLIC OFFERING PRICE OF $13.00/SHARE.GLAXOSMITHKLINE REPORTS 8.3 PCT STAKE IN TRANSLATE BIO INC <<>> AS OF JUNE 27 - SEC FILING .  Full Article

FDA Approves First sANDA For Glenmark Pharma's Manufacturing Facility In Monroe
Monday, 18 Jun 2018 

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::THE US FDA APPROVES FIRST SUPPLEMENTAL ABBREVIATED NEW DRUG APPLICATION (SANDA) FOR GLENMARK PHARMACEUTICALS' MANUFACTURING FACILITY IN MONROE, NORTH CAROLINA.GLENMARK PHARMA - APPROVAL COVERS ATOVAQUONE & PROGUANIL HYDROCHLORIDE TABLETS, 250 MG/100 MG AND 62.5 MG/25 MG.  Full Article

Photo

Long-acting injection a shot in the arm for GSK's HIV business

LONDON A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.